New England Journal of Medicine· 2019Q1
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- 1,951citations
- Q1SCImago
- 2019year
Short summary
This study establishes the cardiovascular safety of oral semaglutide in patients with type 2 diabetes.
AI-generated from the title and abstract; the full text is not read.
Key points
- Cardiovascular safety data for oral semaglutide was needed.
- Oral semaglutide is a glucagon-like peptide-1 receptor agonist.
- The study aimed to establish the cardiovascular safety of oral semaglutide.
- This research provides crucial safety information for a widely used diabetes medication.
AI-generated from the title and abstract; the full text is not read.
Abstract
Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide.
The authors' abstract, as published at the source. New England Journal of Medicine, 2019 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Endocrinology, Diabetes and Metabolism
Endocrinology, Diabetes and MetabolismMedicine